February 22, 2018 5:25pm
Sector intelligence and perspective
… As sector stocks stay up overshadowed by NASDAQ (-0.11%), the IBB (-0.61%) and XLV’s (-0.15%) decline
Defining the balance between pricing, value and risk as …
Volatility is here to stay subsidized by algorithms
Pre-open indication results: 5 hits and 2 miss (1 by pennies)
Quarterly financial and FY17 results: Sangamo Therapeutics (SGMO) Regenerative Medicine Earnings Scorecard - Q4/2017 - to date … https://www.regmedinvestors.com/articles/10142
Out and about: ImmunoCellular Therapeutics (NYSEMKT: IMUC) has initiated review of its “business, assets” and exploration of strategic opportunities. It’s been coming, a dead company - while Capricor (CAPR) is talks a new study of mouse models of Duchenne muscular dystrophy by researchers at Cedars-Sinai Medical Center, who findings of cardiosphere-derived cells (CDCs) improved cardiac muscle function, walking abilities and survival
Review the advance/decline lines of 40 covered companies; daily indication results, trend lines, volatility, daily analytics, the % count of decliners versus gainers and the shifting sands of appreciation:
Thursday’s results have implications to Friday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s newsletter, “…was the upside a trading “tourist” event? Always a sceptic as … the advance/decline line movement was pretty dramatic for the sector. Volume is still low which could set-up a response to yesterday’s upside to re-test lows again?”
Sector stocks traded in a wider trading range Thursday, initiating a two-day winning streak. When “our” universe recover this fast, it usually opens the door for another downturn!
Volume is STILL to the low side with advances that could be SUSPECT tomorrow, Friday!
Pre-open indication results: 5 hits and 2 miss
- AxoGen (AXGN) closed up +$0.15 – miss;
- Bellicum Pharmaceuticals (BLCM) closed up +$0.07 – miss;
- bluebird bio (BLUE) closed down -$6.20 – hit;
- Mesoblast (MESO closed up +$0.57 – hit;
- Regenxbio (RGNX) closed up +$0.45 – hit;
- Sangamo Therapeutics (SGMO) closed up +$3.20 – hit;
- Spark Therapeutics (ONCE) closed up +$2.85 – hit;
The shifting sands of appreciation:
The come-back sector stocks: ADVM (+$0.40), ADRO (+$0.10), AGTC (+$0.15), HSGX (+$0.01), CLLS (+$0.05), STML (+$1.05) and VSTM (+$0.09) and especially AST (+$0.15)
While the downers: XON (-$0.08), NWBO (-$0.02), FCSC (-$0.053), FATE (-$0.01), BLFS (-$0.05), ONVO (-$0.02 after Q3 results) and ATHX (-$0.01) were DUE …
While OSIR (-$0.60) and BLUE (-$6.20 after Q4 and FY17’s missing results) downsides were long overdue …
Surprised by QURE (+$0.44), AXGN (+$0.15), CLBS (+$0.24) and BLCM (+$0.07)
Sliding: KOOL (+$0.09), VCEL (+$0.00), CAPR (+$0.04 on news)
Going nowhere and barely up: BSTG (+$0.00), KOOL (+$0.09) and BCLI (-$0.01)
The advance/decline line scenario of 40 SCGT & RT covered companies:
· The open was positive with an A/DL of 22/13 and 5 flat ;
· The mid-day continued positive with an A/DL of 27/11 and 3 flat;
· The close was positive with an A/DL of 28/10 and 2 flat;
MY working trend lines:
… The greatest volume to the downside: JUNO, MDXG, FCSC, FATE and ONVO
… Upside volume was weighted to: SGMO, IMUC, ADVM, CYTX and ONCE
… Biggest $ downside: BLUE (-$6.20), OSIR (-$0.60), MDXG (-$0.17), JUNO (-$0.08) and XON (-$0.08)
… Largest $ upside: RENE.L (+$3.50), SGMO (+3.20), ONCE (+$2.85), STML (+$1.05) and MESO (+$0.67)
… Flat: CUR and VCEL
Daily analytics:
U.S. stocks rose on Thursday with major indexes on track to snap a multiday skid, following upbeat data on the labor market which may have momentarily offset jitters over inflation and rising bond yields. But the market trimmed gains in the afternoon session as financial stocks slid into negative territory, the lone S&P 500 sector to trade lower in an otherwise upbeat day.
· The Dow gained 177 points, or 0.7%, to 24,960.
· The S&P 500 added 2 points, or 0.1%, to 2,702.
· The NASDAQ turned negative, off 15 points, 0.3%, to 7,203.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Thursday traded at 18.72, down -6.49% …
· Wednesday traded at 20.22, down -2.82% …
· Tuesday traded at 20.60, up +5.86% …
· Monday was a market holiday
· Friday traded 19.46, up +1.73% …
· Last Thursday traded at 19.07, down -0.99% …
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Thursday was down -0.15%
· Wednesday +0.09%
· Tuesday -0.83%
· Monday was a market holiday
· Friday +0.36%
· Last Thursday +1.07%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Thursday was down -0.61%
· Wednesday was down -0.16%
· Tuesday was down -1.01%
· Monday was a market holiday
· Friday was down -0.37%
· Last Thursday was up +0.94%
The count - decliners versus gainers:
……. look at the differences in decliners:
· Thursday’s decliners ranged from -0.09% <JUNO -$0.08> to -8% <FCSC -$0.053> in 10 equities;
· Wednesday’s decliners ranged from -0.15% <BSTG -$0.00> to -10.63% <RENE.L> in 13 equities;
· Tuesday’s decliners ranged from -0.14% <JUNO -$0.12> to -39.53% <MDXG -$5.72> in 26 equities;
· Monday was a market holiday
· Friday’s decliners ranged from -0.31% <STML -$0.05> to -% <CAPR -$0.15> in 17 equities;
· Last Thursday’s decliners ranged from -0.38% <BTX -$0.01> to -10.13% <BSTG -$0.31> in 16 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Thursday’s gainers ranged from +0.15% <CLLS +$0.05> to +14.41% <SGMO +$3.20> in 28 equities;
· Wednesday’s gainers ranged from +0.08% <XON +0.01> to +15.49% <FATE +$1.42> in 24 equities;
· Tuesday’s gainers ranged from +0.39% <FCSC +$0.0026> to +4.70% <BLCM +$0.31> in 12 equities;
· Monday was a market holiday;
· Friday’s gainers ranged from +0.12% <QURE +$0.03> to +10.55% <BLCM +$0.63> in 18 equities;
· Last Thursday’s gainers ranged from +0.63% <STML +$0.10> to +3.55% <ATHX +$0.05> in 20 equities;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
